Posted inCardiology news
Myval THV Demonstrates 1-Year Noninferiority to Established Transcatheter Heart Valves: Insights from the LANDMARK Trial
The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of-life improvements for patients with severe aortic stenosis.